[A double blind cross-over study with mepindolol-sulfate in patients with coronary heart disease (author's transl)].
作者信息
Bonelli J, Magometschnigg D, Schober H, Kleinberger G, Pichler H, Kaik G
出版信息
Wien Med Wochenschr. 1979 Oct 20;129(19):541-6.
PMID:42224
Abstract
UNLABELLED
The effect of mepindolol-sulfate (2 x 2.5 mg) was tested in 20 patients with coronary heart disease in a controlled study against placebo resp. propranolol (3 x 40 mg).
RESULTS
- The frequency and intensity of anginal attacks were reduced significantly under mepindolol-sulfate therapy.-- 2. There was a significant improvement of ergometric exercise tolerance under mepindolol-sulfate therapy.--3. Additionally a reduction of ST-depression in ECG was found under mepindolol-sulfate.--4. In patients with coronary heart disease the clinical effect of mepindolol-sulfate in a daily dose of 2 x 2.5 mg was equal to propranolol in a daily dose of 3 x 40 mg.
摘要
相似文献
1
[A double blind cross-over study with mepindolol-sulfate in patients with coronary heart disease (author's transl)].
Wien Med Wochenschr. 1979 Oct 20;129(19):541-6.
2
3
4
[Anti-ischemic action of the transdermally applied beta-receptor blocker, mepindolol in patients with stable angina pectoris].
Arzneimittelforschung. 1989 Nov;39(11A):1515-7.
5
[Anti-ischemic action of the transdermally-applied beta-receptor blocker, mepindolol, in patients with stable angina pectoris. Comparison with transdermal nitrate].
Arzneimittelforschung. 1990 Aug;40(8):876-9.
6
7
[Ergometric study of the association of a beta-blocker and a nitrate derivative].[β受体阻滞剂与硝酸酯衍生物联合应用的测力计研究]
Nouv Presse Med. 1978 Sep 20;7(31):2727-31.
8
Transdermal delivery of mepindolol and propranolol in normal man. 1st communication: study design, clinical and pharmacodynamic aspects.
Arzneimittelforschung. 1989 Nov;39(11A):1505-8.
9
10
Mepindolol sulfate in the hyperkinetic heart syndrome.硫酸美吡吲哚用于治疗运动亢进性心脏综合征。
Int J Clin Pharmacol Ther Toxicol. 1984 Jan;22(1):42-4.
Zotero 插件